A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Abstract Background In men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy can be combined with SRT in order to increase prostate tumor control, albeit with associated higher rates of treatment side effects. This tr...

Full description

Bibliographic Details
Main Authors: Roche Kapoor, Matthew P. Deek, Riley McIntyre, Natasha Raman, Megan Kummerlowe, Iyah Chen, Matt Gaver, Hao Wang, Sam Denmeade, Tamara Lotan, Channing Paller, Mark Markowski, Michael Carducci, Mario Eisenberger, Tomasz M. Beer, Daniel Y. Song, Theodore L. DeWeese, Jason W. Hearn, Stephen Greco, Curtiland DeVille, Neil B. Desai, Elisabeth I. Heath, Stanley Liauw, Daniel E. Spratt, Arthur Y. Hung, Emmanuel S. Antonarakis, Phuoc T. Tran
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Recurrent prostate cancer
Salvage radiation therapy (SRT)
High-risk prostate cancer
Enzalutamide
Prostatectomy
Online Access:http://link.springer.com/article/10.1186/s12885-019-5805-z

Internet

http://link.springer.com/article/10.1186/s12885-019-5805-z

Similar Items